December 27, 2010 (Mountain View, California) – TIME Magazine named CardioDx's blood-based gene expression test, Corus CAD, one of the Top Ten medical breakthroughs of 2010. The Corus CAD test also won a Technology Innovation Award from The Wall Street Journal this year.
Palo Alto-based CardioDx develops clinically validated tests in the field of cardiovascular genomic diagnostics, strategically focusing on coronary artery disease, cardiac arrhythmia and heart failure. Corus CAD is the first and only clinically validated blood-based test to help clinicians confidently identify which of their stable symptomatic patients are likely to need further assessment for obstructive coronary artery disease.
Fenwick attorneys Michael Shuster, Pauline Farmer-Koppenol, Antonia Sequeira and Kevin Kabler represent CardioDx on intellectual property matters.
Fenwick & West's Life Sciences Industry Group consists of more than 40 attorneys and scientists who provide a broad mix of core legal services to private companies, public companies, investors and research institutions. Many of our Life Sciences Group attorneys have scientific and research experience prior to their legal careers, and a number have advanced technical degrees in disciplines such as molecular biology, organic chemistry, electrical engineering, and immunology. For more information, visit the Life Science Industry Group page.